Trial
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Pediatric Cancer (Oncology)
Rhabdomyosarcoma (High Risk)
This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with combination chemotherapy may kill more tumor cells.
Patients must be eligible for and enrolled on D9902 prior to enrollment on ARST08P1
Age for embryonal RMS: Age > 10 years and < 50 years at the time of enrollment
Age for alveolar RMS or ectomesenchymoma: Age <50 years at the time of enrollment
Patients with newly diagnosed, biopsy proven metastatic rhabdomyosarcoma or
ectomesenchymoma (Stage IV, Clinical Group IV) are eligible for this study
No prior chemotherapy or radiation therapy except for use of corticosteroids or emergent radiation therapy
Adequate kidney, liver, heart, and hematological (blood counts) functions
Principal Investigator Name
Janice Olson, MD
Children's Cancer and Blood Disorders Program
Last Updated:
Wednesday, January 27, 2021 11:41:31 AM